Answers are grounded in this paper and cite their sources.
Network meta-analysis reveals varied benefits among topical eye drops in post-cataract surgery patients, highlighting that no single regimen consistently optimizes all ocular-surface outcomes.
Postoperative dry eye can impair visual recovery and patients’ perceived benefit after cataract surgery. We compared topical eye-drop regimens across tear-film stability, tear secretion, corneal epithelial damage, and patient-reported symptoms. A PROSPERO-registered review searched nine databases from inception to January 30, 2026, for randomized trials of ocular-surface treatments after cataract surgery. Frequentist random-effects network meta-analyses assessed 1-month tear-film breakup time, Schirmer test, corneal fluorescein staining, and Ocular Surface Disease Index; safety was summarized descriptively. Forty-seven trials (102 arms; 4920 eyes assessed; 4844 arm-level analyzed observations) were included; 38 trials (81 arms; 3898 analysis units) contributed to network meta-analyses within a 19-node framework. Compared with routine postoperative care, moderate-confidence evidence indicated greater tear-film breakup time with diquafosol plus hyaluronic acid (mean difference 4.17 s, 95% confidence interval 1.99–6.35) and cyclosporine plus carboxymethylcellulose (3.97 s, 1.60–6.34), whereas low-confidence evidence suggested a possible increase with cyclosporine plus deproteinized calf blood extract (4.98 s, 1.93–8.03). Outcome-specific benefits were observed for tear secretion and corneal staining, whereas symptom findings were exploratory. Most top-ranked treatment nodes across the four networks were informed by only one or two trials with few analysis units. Some estimates were affected by high risk of bias or local incoherence. No statistically significant global inconsistency was detected overall. No single topical regimen showed consistently favorable effects across all postoperative ocular-surface outcomes. Outcome-specific signals require confirmation because sparse direct evidence, risk of bias, and limited safety and longer-term data preclude definitive recommendations. Adequately powered head-to-head trials with standardized postoperative care are needed for future clinical guidance. PROSPERO CRD42026138249. Dry eye can develop or worsen after cataract surgery and may cause discomfort, unstable vision, and slower visual recovery. We reviewed 47 randomized trials of eye drops used before or after cataract surgery; 38 contributed to one or more combined treatment comparisons at 1 month. The treatments were grouped into 19 clearly defined regimens and were compared for tear-film stability, tear production, damage to the corneal surface, symptoms reported by patients, and safety. No single regimen performed best across all outcomes. Some treatments aimed at reducing inflammation, increasing tear production, or supporting repair of the eye surface showed favorable results for particular outcomes. However, several apparently promising treatments were supported by only one or two small trials, and some estimates were affected by study limitations or disagreement between different sources of evidence. Findings for symptoms were exploratory, while adverse events and longer-term outcomes were reported too inconsistently for firm conclusions. Participants were mainly middle-aged or older adults, and most evidence came from East Asia and Europe; race or ethnicity was rarely reported, which may limit how widely the findings apply. These results identify treatments that deserve further direct comparison, but they should not be used to choose treatment solely from statistical rankings. Larger, well-designed trials with standardized postoperative care and longer follow-up are needed.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: